Clinical Cancer Research, Vol 2, Issue 4 669-677, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity

NJ Meropol, M Porter, LE Blumenson, MJ Lindemann, RP Perez, L Vaickus, GM Loewen, PJ Creaven, KA Wilkes, MA Giedlin and MA Caligiuri
Divisions of Medicine, Molecular Medicine, Molecular Immunology, and Biostatistics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

We aimed to determine the toxicity and immunological effects of daily s.c. administered low-dose interleukin (IL) 2. Adult cancer patients received a single daily s.c. injection of IL-2 as outpatients for 90 consecutive days. Cohorts of four to nine patients were treated at escalating IL-2 dose levels until the maximum tolerated dose (MTD) was defined. Peripheral blood mononuclear cell phenotyping, IL-2 serum levels, and the presence of anti-IL-2 antibodies were investigated. Thirty-eight patients were treated at seven IL-2 dose levels ranging from 0.4 to 1.75 million International Units (mIU)/m2 daily. The MTD was 1.25 mIU/m2, with constitutional side effects, vomiting, and hyperglycemia dose limiting. Severe toxicity did not occur at or below the MTD, although mild local skin reaction and mild constitutional side effects were common. Objective tumor regressions were not observed during this Phase I trial. Low-dose IL-2 resulted in natural killer (NK) cell (CD3(-) CD56(+)) expansion at all dose levels. This effect was dose dependent (P < 0.01), ranging from a 154 to 530% increase over baseline. Peak NK levels were achieved at 6-8 weeks and sustained through 12 weeks of therapy. As predicted by in vitro studies of IL-2 receptor structure-activity relationships, the subset of NK cells that constitutively express high-affinity IL-2 receptors (CD3(-)CD56(bright+)) showed more profound dose-dependent expansion, with increases ranging from 368 to 2763% (P = 0.015). NK expansion occurred at peak IL-2 levels <10 pM (2.3 IU/ml). Three patients developed nonneutralizing anti-IL-2 antibodies. Thus, we concluded that selective expansion of NK cells may be achieved in vivo with daily s.c. injections of low-dose IL-2 with minimal toxicity.

This article has been cited by other articles:

				M. Brune, S. Castaigne, J. Catalano, K. Gehlsen, A. D. Ho, W.-K. Hofmann, D. E. Hogge, B. Nilsson, R. Or, A. I. Romero, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood, July 1, 2006; 108(1): 88 - 96. [Abstract] [Full Text] [PDF]

				C. F. Eisenbeis, A. Grainger, B. Fischer, R. A. Baiocchi, L. Carrodeguas, S. Roychowdhury, L. Chen, A. L. Banks, T. Davis, D. Young, et al. Combination Immunotherapy of B-Cell Non-Hodgkin's Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study Clin. Cancer Res., September 15, 2004; 10(18): 6101 - 6110. [Abstract] [Full Text] [PDF]

				W. L. Gluck, D. Hurst, A. Yuen, A. M. Levine, M. A. Dayton, J. P. Gockerman, J. Lucas, K. Denis-Mize, B. Tong, D. Navis, et al. Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma: IL-2 Mediated Natural Killer Cell Expansion Correlations with Clinical Response Clin. Cancer Res., April 1, 2004; 10(7): 2253 - 2264. [Abstract] [Full Text] [PDF]

				I. D. Davis, M. Jefford, P. Parente, and J. Cebon Rational approaches to human cancer immunotherapy J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29. [Abstract] [Full Text] [PDF]

				G. F. Fleming, N. J. Meropol, G. L. Rosner, D. R. Hollis, W. E. Carson III, M. Caligiuri, J. Mortimer, K. Tkaczuk, R. Parihar, R. L. Schilsky, et al. A Phase I Trial of Escalating Doses of Trastuzumab Combined with Daily Subcutaneous Interleukin 2: Report of Cancer and Leukemia Group B 9661 Clin. Cancer Res., December 1, 2002; 8(12): 3718 - 3727. [Abstract] [Full Text] [PDF]

				S. S. Farag, S. L. George, E. J. Lee, M. Baer, R. K. Dodge, B. Becknell, T. Fehniger, L. R. Silverman, J. Crawford, C. D. Bloomfield, et al. Postremission Therapy with Low-dose Interleukin 2 with or without Intermediate Pulse Dose Interleukin 2 Therapy Is Well Tolerated in Elderly Patients with Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 9420 Clin. Cancer Res., September 1, 2002; 8(9): 2812 - 2819. [Abstract] [Full Text] [PDF]

				T. A. Fehniger and M. A. Caligiuri Interleukin 15: biology and relevance to human disease Blood, January 1, 2001; 97(1): 14 - 32. [Full Text] [PDF]

				J. S. Miller, T. Cervenka, J. Lund, I. J. Okazaki, and J. Moss Purine Metabolites Suppress Proliferation of Human NK Cells Through a Lineage-Specific Purine Receptor J. Immunol., June 15, 1999; 162(12): 7376 - 7382. [Abstract] [Full Text] [PDF]

				T. A. Fehniger, M. H. Shah, M. J. Turner, J. B. VanDeusen, S. P. Whitman, M. A. Cooper, K. Suzuki, M. Wechser, F. Goodsaid, and M. A. Caligiuri Differential Cytokine and Chemokine Gene Expression by Human NK Cells Following Activation with IL-18 or IL-15 in Combination with IL-12: Implications for the Innate Immune Response J. Immunol., April 15, 1999; 162(8): 4511 - 4520. [Abstract] [Full Text] [PDF]

				J. A. Hank, J. Surfus, J. Gan, M. Albertini, M. Lindstrom, J. H. Schiller, K. M. Hotton, M. Khorsand, and P. M. Sondel Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations Clin. Cancer Res., February 1, 1999; 5(2): 281 - 289. [Abstract] [Full Text] [PDF]

				T. A. Fehniger, W. E. Carson, E. Mrozek, and M. A. Caligiuri Stem Cell Factor Enhances Interleukin-2-Mediated Expansion of Murine Natural Killer Cells In Vivo Blood, November 1, 1997; 90(9): 3647 - 3653. [Abstract] [Full Text] [PDF]